


LEGEND-T2DM Evidence Dissemination Summary

Target: **sitagliptin**, Comparator: **glipizide** Outcome: **Renal cancer** Subgroup: **All**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Nr. of outcomes	IR (/1,000 PY)
CCAE	81,973	69,654	66	0.95
Clinformatics	38,252	30,601	62	2.03
DA Germany	-	-	-	-
LDP France	-	-	-	-
MDCD	8,394	5,918	10	1.69
MDCR	11,528	10,807	21	1.94
Open Claims	612,304	536,922	514	0.96
Optum EHR	56,636	25,766	30	1.16
Veterans Affairs	1,050	1,108	<10	<9.03

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

